Chronic Pain Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Chronic pain is defined as pain persisting for more than 3 months, beyond the expected period of tissue healing, and is now recognised as a disease in its own right — chronic primary pain or chronic secondary pain — as classified in the ICD-11 (2019). Unlike acute pain, which serves a biological warning function, chronic pain reflects persistent sensitisation of the nervous system rather than ongoing tissue damage. It affects approximately 20% of the global population (1.5 billion people), is the leading cause of disability worldwide, and has enormous socioeconomic impact. The pathophysiology involves peripheral sensitisation (lowered threshold of nociceptors), central sensitisation (amplified processing in the spinal cord and brain), altered descending inhibitory control, and neuroinflammatory changes — compounded by psychological factors including pain catastrophising, fear-avoidance behaviour, depression, anxiety, and sleep disorders that amplify the pain experience. Modern chronic pain management adopts the biopsychosocial model — simultaneously addressing biological (nociception, tissue pathology, neurological sensitisation), psychological (emotions, beliefs, coping strategies), and social (work, relationships, socioeconomic) dimensions. Treatment is rarely curative; the goal is to reduce pain, improve function, enhance quality of life, and reduce the impact of pain on daily activities. Opioids are generally not first-line and often not appropriate for chronic non-cancer pain — evidence consistently shows they provide limited long-term benefit with high addiction and harm risk. Multidisciplinary pain rehabilitation programmes (MPRPs) combining physiotherapy, psychology, education, and occupational therapy produce the best outcomes.

Chronic pain treatment encompasses: chronic primary pain — fibromyalgia, complex regional pain syndrome (CRPS), chronic widespread musculoskeletal pain, chronic pelvic pain, chronic headache (migraine, tension-type, medication-overuse headache), irritable bowel syndrome with pain, and chronic non-specific low back or neck pain without clear structural cause. Chronic secondary pain — pain arising from or clearly associated with underlying disease: chronic musculoskeletal pain (osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, degenerative disc disease); neuropathic pain (diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, phantom limb pain, central post-stroke pain, chemotherapy-induced peripheral neuropathy, spinal cord injury pain); visceral pain (pancreatitis, interstitial cystitis, endometriosis pain, post-surgical adhesion pain); and cancer-related chronic pain (bone metastasis, post-treatment neuropathy, lymphoedema). Each condition requires a tailored approach recognising the specific pathophysiology, maintaining function, addressing comorbid depression and anxiety, and supporting occupational re-integration.

Patients with pain lasting more than 3 months that has not responded adequately to primary care management, causing significant functional impairment or reduced quality of life, should be referred to a specialist pain management clinic or multidisciplinary pain centre. Comprehensive pain assessment at a specialist centre includes: detailed pain history (onset, character, severity, temporal pattern, aggravating and relieving factors); functional assessment (activity levels, sleep quality, work and social participation); psychological assessment (PHQ-9 depression screening, GAD-7 anxiety screening, Pain Catastrophising Scale, Fear Avoidance Beliefs Questionnaire); physical examination; and selective investigation to identify any treatable underlying structural or neuropathic pathology. Multidisciplinary assessment is the gold standard — patient seen by pain physician, psychologist, physiotherapist, occupational therapist, and if needed, social worker, all working collaboratively. The patient's goals, beliefs about pain, readiness to engage in active self-management, and psychological readiness for a rehabilitation approach rather than passive treatment are assessed. Patients with active substance misuse disorder require concurrent addiction medicine management alongside pain treatment.

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

Multidisciplinary pain rehabilitation programmes (MPRPs) achieve the best outcomes for complex chronic pain, producing 30–40% reduction in pain intensity, 40–50% improvement in function and work participation, and significant reductions in healthcare utilisation and medication use — superior to single-modality treatment or continued opioid management. Cognitive behavioural therapy (CBT) for chronic pain reduces pain intensity by approximately 20%, catastrophising by 30–40%, and depression by 30–40%, with improvements maintained at 12-month follow-up. Acceptance and Commitment Therapy (ACT) focuses on psychological flexibility and values-based living despite pain — evidence shows similar benefits to CBT in chronic pain. Physiotherapy with active exercise improves function, reduces fear-avoidance, and increases pain threshold. Pharmacological management: tricyclic antidepressants (amitriptyline) and SNRIs (duloxetine) achieve 30–40% pain reduction in neuropathic pain and fibromyalgia. Pregabalin and gabapentin are effective for neuropathic pain (NNT approximately 4–6). Spinal cord stimulation achieves 50% or greater pain reduction in 50–70% of carefully selected patients with CRPS, failed back surgery syndrome, or painful diabetic neuropathy. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are emerging neuromodulation tools for central sensitisation syndromes.

Pharmacological risks: opioids in chronic non-cancer pain carry significant risks of dependence, addiction, opioid-induced hyperalgesia (paradoxical pain worsening with escalating doses), cognitive impairment, hormonal dysfunction, falls and fractures, and overdose death — they should be used only with clear indication, monitoring, and regular review. NSAIDs cause GI, cardiovascular, and renal adverse effects with long-term use. Tricyclics cause anticholinergic side effects (dry mouth, constipation, urinary retention) and cardiac effects at high doses. Pregabalin and gabapentin cause drowsiness, dizziness, and weight gain; they carry addiction potential and have become drugs of misuse. Benzodiazepines are contraindicated in chronic pain — they increase pain catastrophising, impair sleep architecture, and carry high dependence risk. Interventional procedures carry procedure-specific risks (infection, nerve injury, haematoma). The risk of medicalisation — excessive investigations, surgical interventions without clear benefit, and opioid escalation — must be actively countered through patient education and a self-management approach. Psychological barriers to recovery — learned helplessness, depression, pain catastrophising — can prevent treatment engagement and must be addressed proactively.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

Chronic pain management in India is substantially more affordable. Pain specialist consultation costs USD 30–80 per visit. Generic duloxetine costs USD 5–20 per month; pregabalin USD 10–30 per month; amitriptyline USD 3–10 per month. Psychological consultation (CBT for pain) costs USD 30–70 per session; 12-session CBT programme costs USD 400–900. Physiotherapy USD 15–40 per session. Transcutaneous electrical nerve stimulation (TENS) unit costs USD 30–80. Interventional procedures: epidural steroid injection USD 200–600; facet joint radiofrequency ablation USD 800–2,000; spinal cord stimulator implantation USD 15,000–30,000 in India versus USD 50,000–100,000 in the USA. Multidisciplinary pain rehabilitation programmes (inpatient or intensive day programmes) cost USD 2,000–6,000 for 4–6 weeks in India. In the USA, MPRP programmes cost USD 15,000–50,000; opioid prescriptions cost USD 50–500 per month without insurance; spinal cord stimulators USD 50,000–100,000. India offers experienced pain specialists (many UK and USA trained), modern interventional pain suites, and comprehensive multidisciplinary pain centres at leading hospitals (Apollo, Fortis, Medanta, Amrita).

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.